Matt Sagan, Disruptive Innovations Funding and Mentoring, Co-Founder and Angel Investor, shared a post by Eric Topol, Executive Vice-President of Scripps Research on X:
“Cancer vaccines are gaining momentum
An important and interesting pathway to fight the most aggressive cancer types.”
Quoting Eric Topol’s post:
“Cancer vaccines to rev up a person’s immune response to a tumor are gaining momentum, even vs some of the most aggressive types.
One unsettled question: why does the immune system overlook a neoantigen produced by a tumour, but gets activated when it is delivered by a vaccine?
Find more information here.”
More posts featuring Matt Sagan and Eric Topol.